Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III desensitization and pre-transplant tacrolimus study in living donor kidney transplantation
jRCT2080224107Phase 3Completed
- Sponsor
- Nippon Zenyaku Kogyo Co., Ltd.
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of rituximab and tacrolimus in kidney failure, Allosensitization and alloimmunization (3 arms), sponsored by Nippon Zenyaku Kogyo Co., Ltd. Started Oct 2018; status: completed.
02
Drugs
rituximabtacrolimus
03
Conditions
kidney failureAllosensitizationalloimmunization
Beyond the preview
Go deeper on jRCT2080224107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224107.